| Sarkis Boghossian, PHARM D | |
|
6648 Zelzah Ave, Reseda, CA 91335-5623 | |
| (818) 522-8184 | |
| Not Available |
| Full Name | Sarkis Boghossian |
|---|---|
| Gender | Male |
| Speciality | Pharmacist |
| Location | 6648 Zelzah Ave, Reseda, California |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1184060683 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 183500000X | Pharmacist | 54979 (California) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Sarkis Boghossian, PHARM D 6648 Zelzah Ave, Reseda, CA 91335-5623 Ph: () - | Sarkis Boghossian, PHARM D 6648 Zelzah Ave, Reseda, CA 91335-5623 Ph: (818) 522-8184 |
News Archive
Suicidal thoughts and attempts by adult transgender individuals were 14 and 22 times higher, respectively, than rates for the general public, according to a new study published in Transgender Health, a peer-reviewed open access journal from Mary Ann Liebert, Inc., publishers. The article is available open access on the Transgender Health website.
A well-known, four-year study found popular arthritis drug Celebrex no more dangerous for the heart than older drugs in its same classification - commonly called NSAIDs.
Cancer cells need food to survive and grow. They're very good at getting it, too, even when nutrients are scarce. Many scientists have tried killing cancer cells by taking away their favorite food, a sugar called glucose. Unfortunately, this treatment approach not only fails to work, it backfires-glucose-starved tumors actually get more aggressive.
Geron Corporation today announced the presentation of interim data from its phase II trial of GRNVAC1, an autologous dendritic cell vaccine targeting telomerase, in patients with acute myelogenous leukemia (AML) at the 51st Annual Meeting of the American Society of Hematology (ASH) in New Orleans, Louisiana.
Ceregene, Inc., a biopharmaceutical company, reported today that its scientists and collaborators have published new experimental findings in support of its Parkinson's disease program which appeared as the lead article in the current issue of Movement Disorders. The publication reports the first evidence that gene transfer can provide targeted expression of a neurotrophic factor, i.e., neurturin or NRTN, intended to restore and preserve dying neurons.
› Verified 4 days ago
Darya Kraynova, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 18647 Keswick St, Reseda, CA 91335 Phone: 818-390-1878 | |
Mina Shaafi, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 18430 Sherman Way, Reseda, CA 91335 Phone: 818-343-4513 | |
Mr. Wasem Eshak, R.PH Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 7742 Darby Ave, Reseda, CA 91335 Phone: 310-210-0142 | |
Shawnt Zohrab Batmanian, PHARM D. Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 7522 Nestle Ave, Reseda, CA 91335 Phone: 818-468-7263 | |
Aviva Azarfar, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 18430 Sherman Way, Reseda, CA 91335 Phone: 818-343-4513 | |
Payal Patel, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 7400 Reseda Blvd, Reseda, CA 91335 Phone: 818-776-2600 | |
Mrs. Tina Chelsea Korbelas, PHARM D Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 18430 Sherman Way, Reseda, CA 91335 Phone: 818-343-4513 |